China's Leading Center for Blood Cancer & Hematological Disease
The Department of Hematology at Ruijin Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is widely regarded as the finest hematology center in China and one of the most distinguished in Asia. Renowned for its pioneering contributions to leukemia research, its world-class bone marrow transplantation program, and its leadership in the development of novel therapies for lymphoma, myeloma, and myeloid malignancies, the department attracts patients from across China and internationally who are seeking the highest standard of hematological care.
For international patients with leukemia, lymphoma, myeloma, or other blood disorders, Ruijin Hospital's hematology department represents one of the most compelling destinations for expert diagnosis, second opinion, and cutting-edge treatment in Asia. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination — from medical record translation and specialist scheduling to on-site accompaniment and post-treatment follow-up.
About the Department
Ruijin Hospital's hematology department is a national key clinical specialty and one of the most research-active hematology centers in the world. The department is home to the Shanghai Institute of Hematology — a world-renowned research institution that has produced landmark discoveries in leukemia biology and treatment, most notably the development of all-trans retinoic acid (ATRA) therapy for acute promyelocytic leukemia (APL) — a breakthrough that transformed APL from one of the most lethal leukemias into one of the most curable, and earned international recognition as one of the greatest achievements in modern oncology.
The department operates dedicated inpatient hematology wards, a bone marrow transplantation unit (BMT), a hematology day treatment center for outpatient chemotherapy and infusions, a stem cell collection facility, a comprehensive hematology laboratory, and an active clinical trials program. It is one of the few centers in China with the full range of transplantation capabilities including allogeneic, autologous, and haploidentical (half-matched) bone marrow transplantation.
Faculty members publish regularly in the world's leading hematology and oncology journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, Nature Medicine, and Leukemia.
Conditions Treated
Leukemia
- Acute Myeloid Leukemia (AML) — Comprehensive management including intensive induction chemotherapy, targeted therapy (FLT3 inhibitors, IDH inhibitors, venetoclax combinations), and allogeneic stem cell transplantation
- Acute Promyelocytic Leukemia (APL) — The birthplace of ATRA therapy; world-leading expertise in APL management with cure rates exceeding 90% using ATRA + arsenic trioxide protocols
- Acute Lymphoblastic Leukemia (ALL) — Pediatric and adult ALL; Philadelphia chromosome-positive ALL with TKI combinations; CAR-T cell therapy for relapsed/refractory disease
- Chronic Myeloid Leukemia (CML) — TKI therapy (imatinib, dasatinib, nilotinib, ponatinib, asciminib); treatment-free remission protocols; blast crisis management
- Chronic Lymphocytic Leukemia (CLL) — BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), venetoclax combinations, and chemoimmunotherapy
Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL) — R-CHOP and intensified regimens; CAR-T cell therapy (axicabtagene ciloleucel, lisocabtagene maraleucel) for relapsed/refractory disease
- Follicular Lymphoma & Indolent B-Cell Lymphomas — Watch-and-wait, rituximab-based therapy, and PI3K inhibitors
- Mantle Cell Lymphoma — BTK inhibitors, intensive chemotherapy, and autologous stem cell transplantation
- Hodgkin Lymphoma — ABVD and escalated BEACOPP; brentuximab vedotin; PD-1 inhibitors for relapsed disease
- T-Cell Lymphomas — PTCL, AITL, ALCL, and NK/T-cell lymphoma; CHOP-based regimens and novel agents
- Primary CNS Lymphoma — High-dose methotrexate-based therapy and autologous stem cell transplantation
Multiple Myeloma & Plasma Cell Disorders
- Multiple Myeloma — Proteasome inhibitors (bortezomib, carfilzomib, ixazomib), IMiDs (lenalidomide, pomalidomide), anti-CD38 antibodies (daratumumab, isatuximab), autologous stem cell transplantation, and CAR-T cell therapy (ciltacabtagene autoleucel, idecabtagene vicleucel)
- Smoldering Myeloma & MGUS — Risk stratification and surveillance; early intervention for high-risk smoldering myeloma
- Amyloidosis (AL) — Plasma cell-directed therapy and organ support
- Waldenstrom's Macroglobulinemia — BTK inhibitors and rituximab-based therapy
Myeloid Disorders
- Myelodysplastic Syndromes (MDS) — Risk stratification (IPSS-R, IPSS-M), hypomethylating agents (azacitidine, decitabine), lenalidomide for del(5q), and allogeneic stem cell transplantation for high-risk disease
- Myeloproliferative Neoplasms (MPN) — Polycythemia vera, essential thrombocythemia, and myelofibrosis; JAK inhibitors (ruxolitinib, fedratinib, pacritinib); stem cell transplantation for advanced myelofibrosis
- Aplastic Anemia — Immunosuppressive therapy (ATG + cyclosporine + eltrombopag) and allogeneic stem cell transplantation
- Paroxysmal Nocturnal Hemoglobinuria (PNH) — Complement inhibitors (eculizumab, ravulizumab, iptacopan)
Other Hematological Conditions
- Hemophilia & Bleeding Disorders — Factor replacement therapy, emicizumab, and gene therapy coordination
- Immune Thrombocytopenia (ITP) — Corticosteroids, TPO receptor agonists (eltrombopag, romiplostim), rituximab, and splenectomy coordination
- Autoimmune Hemolytic Anemia — Corticosteroids, rituximab, and complement inhibitors
- Thalassemia — Transfusion management, chelation therapy, and stem cell transplantation for eligible patients
Leading Specialists
Prof. Zhao Weili (赵维莞) — Director, Hematology
Prof. Zhao Weili is one of China's most distinguished hematologists and a globally recognized authority in lymphoma biology and treatment. As Director of the Department of Hematology at Ruijin Hospital, she leads one of China's most productive hematology research and clinical programs. Prof. Zhao's research has made fundamental contributions to the understanding of lymphoma pathogenesis, particularly in diffuse large B-cell lymphoma and T-cell lymphomas, with landmark publications in Nature Medicine, Blood, and Journal of Clinical Oncology. Her clinical program is at the forefront of CAR-T cell therapy for relapsed/refractory lymphoma in China, and she has been instrumental in bringing novel immunotherapy agents to Chinese patients through clinical trials.
Prof. Chen Saijuan (陈赛娟) — Academician, Chinese Academy of Sciences & Engineering
Prof. Chen Saijuan is one of China's most celebrated biomedical scientists and a co-discoverer of the arsenic trioxide (ATO) therapy for acute promyelocytic leukemia — a discovery that, combined with ATRA, has made APL one of the most curable cancers in the world. Elected as an Academician of both the Chinese Academy of Sciences and the Chinese Academy of Engineering, Prof. Chen has dedicated her career to translational hematology research — bridging laboratory discoveries to clinical breakthroughs. Her work on APL, leukemia genomics, and targeted therapy has been published in the world's most prestigious scientific journals and has saved tens of thousands of lives globally.
Bone Marrow Transplantation Program
Ruijin Hospital's bone marrow transplantation (BMT) program is one of the most experienced and highest-volume in China, performing hundreds of transplants annually across all major indications:
- Allogeneic Stem Cell Transplantation — Matched sibling, matched unrelated donor (MUD), and haploidentical (half-matched) transplantation for leukemia, MDS, aplastic anemia, and other hematological malignancies
- Autologous Stem Cell Transplantation — High-dose chemotherapy with autologous stem cell rescue for lymphoma, myeloma, and selected solid tumors
- Cord Blood Transplantation — Single and double cord blood transplantation for patients without a matched donor
- Reduced-Intensity Conditioning (RIC) — Non-myeloablative and reduced-intensity regimens for older patients or those with comorbidities
- Post-Transplant Management — GVHD prophylaxis and treatment, infection management, and long-term survivorship care
CAR-T Cell Therapy
Ruijin Hospital is one of China's leading centers for CAR-T cell therapy — a revolutionary immunotherapy that has transformed outcomes for patients with relapsed or refractory B-cell lymphomas, ALL, and multiple myeloma. The department has extensive experience with both approved commercial CAR-T products and investigational CAR-T constructs through clinical trials, offering patients access to this cutting-edge therapy within a highly experienced clinical program.
Why International Patients Choose Ruijin Hematology
- World-Leading APL Expertise — The birthplace of ATRA and ATO therapy for APL; unmatched global expertise in this condition
- Comprehensive Transplant Program — Full range of allogeneic, autologous, haploidentical, and cord blood transplantation
- CAR-T Cell Therapy — One of China's most experienced CAR-T programs for lymphoma, ALL, and myeloma
- Clinical Trial Access — Active participation in national and international trials providing access to next-generation hematological therapies
- Academic Excellence — Home to the Shanghai Institute of Hematology; publications in NEJM, Nature Medicine, and Blood
- Cost-Effectiveness — World-class hematological care at significantly lower cost than equivalent treatment in the US, UK, or Australia
The CMCS Patient Journey
- Initial Inquiry — Share your diagnosis, bone marrow biopsy reports, cytogenetics, molecular profiling, prior treatment history, and current medications with CMCS.
- Medical Record Preparation — We translate and organize your hematology records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate hematologist based on your specific diagnosis — leukemia, lymphoma, myeloma, MDS, or transplantation.
- Priority Scheduling — We secure a consultation with minimal waiting time, including urgent slots for rapidly progressing disease.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near Ruijin Hospital, and Shanghai airport transfers.
- On-Site Concierge — Bilingual coordinators accompany you throughout your hospital visits, managing registration, translation, and communication with your hematology team.
- Treatment Coordination — Full coordination of bone marrow biopsy, molecular testing, chemotherapy scheduling, transplant workup, and CAR-T cell therapy logistics.
- Post-Treatment Follow-Up — Lab result translation, treatment response assessment, and remote follow-up coordination after you return home.
Book a Consultation
If you are seeking expert hematology care in Shanghai — whether for leukemia, lymphoma, myeloma, MDS, aplastic anemia, or bone marrow transplantation — CMCS can arrange a specialist consultation with Ruijin Hospital's world-renowned hematology team.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 commentaire